A new biomarker classification system for AD, independent of cognition

Agnosticism is a start

Research output: Contribution to journalEditorial

Abstract

Clinicians and researchers interested in Alzheimer disease (AD) are confronted with an expanding number of biomarkers that can be derived from brain imaging and CSF analysis. But how do we make sense of specific and nonspecific disease indicators that increasingly coexist in normal and diseased older people? In this issue of Neurology®, Jack et al.1 present us with a scheme that indicates the binary presence or absence of 7 biomarkers in 3 categories of amyloid (A), tau (T), and neurodegeneration (N): the A/T/N classification system. The rationale for such a new descriptive system for categorizing multidomain biomarkers is 4-fold: (1) the advent of tau PET tracers providing an imaging biomarker of tau neuropathology; (2) the uncertainty regarding the temporal relationships among current β-amyloid (Aβ) and tau biomarkers; (3) independence from diagnostic classification schemes that are not directly related to biomarkers, particularly independence from diagnostic classification based on cognition; and (4) the need to include all biomarker profiles that are found in all members of the population. The rationale is laudable, but how far does the proposed A/T/N classification scheme go toward achieving this?
Original languageEnglish
Pages (from-to)456-457
Number of pages2
JournalNeurology
Volume87
Issue number5
Early online date1 Jul 2016
DOIs
Publication statusPublished - 2 Aug 2016

Fingerprint

Cognition
Alzheimer Disease
Biomarkers
Amyloid
Neurology
Neuroimaging
Uncertainty
Research Personnel
Population

Cite this

A new biomarker classification system for AD, independent of cognition : Agnosticism is a start. / Murray, Alison D.

In: Neurology, Vol. 87, No. 5, 02.08.2016, p. 456-457.

Research output: Contribution to journalEditorial

@article{aced71dfc4fd4f3fb833458b20cd2acc,
title = "A new biomarker classification system for AD, independent of cognition: Agnosticism is a start",
abstract = "Clinicians and researchers interested in Alzheimer disease (AD) are confronted with an expanding number of biomarkers that can be derived from brain imaging and CSF analysis. But how do we make sense of specific and nonspecific disease indicators that increasingly coexist in normal and diseased older people? In this issue of Neurology{\circledR}, Jack et al.1 present us with a scheme that indicates the binary presence or absence of 7 biomarkers in 3 categories of amyloid (A), tau (T), and neurodegeneration (N): the A/T/N classification system. The rationale for such a new descriptive system for categorizing multidomain biomarkers is 4-fold: (1) the advent of tau PET tracers providing an imaging biomarker of tau neuropathology; (2) the uncertainty regarding the temporal relationships among current β-amyloid (Aβ) and tau biomarkers; (3) independence from diagnostic classification schemes that are not directly related to biomarkers, particularly independence from diagnostic classification based on cognition; and (4) the need to include all biomarker profiles that are found in all members of the population. The rationale is laudable, but how far does the proposed A/T/N classification scheme go toward achieving this?",
author = "Murray, {Alison D}",
year = "2016",
month = "8",
day = "2",
doi = "10.1212/WNL.0000000000002931",
language = "English",
volume = "87",
pages = "456--457",
journal = "Neurology",
issn = "0028-3878",
publisher = "AAN Enterprises",
number = "5",

}

TY - JOUR

T1 - A new biomarker classification system for AD, independent of cognition

T2 - Agnosticism is a start

AU - Murray, Alison D

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Clinicians and researchers interested in Alzheimer disease (AD) are confronted with an expanding number of biomarkers that can be derived from brain imaging and CSF analysis. But how do we make sense of specific and nonspecific disease indicators that increasingly coexist in normal and diseased older people? In this issue of Neurology®, Jack et al.1 present us with a scheme that indicates the binary presence or absence of 7 biomarkers in 3 categories of amyloid (A), tau (T), and neurodegeneration (N): the A/T/N classification system. The rationale for such a new descriptive system for categorizing multidomain biomarkers is 4-fold: (1) the advent of tau PET tracers providing an imaging biomarker of tau neuropathology; (2) the uncertainty regarding the temporal relationships among current β-amyloid (Aβ) and tau biomarkers; (3) independence from diagnostic classification schemes that are not directly related to biomarkers, particularly independence from diagnostic classification based on cognition; and (4) the need to include all biomarker profiles that are found in all members of the population. The rationale is laudable, but how far does the proposed A/T/N classification scheme go toward achieving this?

AB - Clinicians and researchers interested in Alzheimer disease (AD) are confronted with an expanding number of biomarkers that can be derived from brain imaging and CSF analysis. But how do we make sense of specific and nonspecific disease indicators that increasingly coexist in normal and diseased older people? In this issue of Neurology®, Jack et al.1 present us with a scheme that indicates the binary presence or absence of 7 biomarkers in 3 categories of amyloid (A), tau (T), and neurodegeneration (N): the A/T/N classification system. The rationale for such a new descriptive system for categorizing multidomain biomarkers is 4-fold: (1) the advent of tau PET tracers providing an imaging biomarker of tau neuropathology; (2) the uncertainty regarding the temporal relationships among current β-amyloid (Aβ) and tau biomarkers; (3) independence from diagnostic classification schemes that are not directly related to biomarkers, particularly independence from diagnostic classification based on cognition; and (4) the need to include all biomarker profiles that are found in all members of the population. The rationale is laudable, but how far does the proposed A/T/N classification scheme go toward achieving this?

U2 - 10.1212/WNL.0000000000002931

DO - 10.1212/WNL.0000000000002931

M3 - Editorial

VL - 87

SP - 456

EP - 457

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -